Low CYP-affinity. Probably not significantly metabolised

Statin type HMG-CoA reductase inhibitor used in treatment of hyperlipidemia, tabl. 30-120 mg/d. Distributed to the liver but metabolized only to a minor (10 %) extent. About 90 % of the dose is excreted in unchanged form infaeces. In vitro- and in vivo studies show that the substance is neither inhibitor , nor inducer of CYPs.

Uneventful use reported in 31 patients with acute porphyria.